Tuesday, November 17, 2026

Buzzreach and Medley M3 form capital and business alliance to promote clinical trial DX

Buzzreach, which aims to solve issues in new drug development by developing a platform specialized in clinical trials and clinical research, centered on its clinical trial DX SaaS "Study Works®︎" and patient recruitment support, has concluded a capital and business alliance agreement with MEDRay and M3, and raised funds from DG Resona Ventures No. 1 Investment Business Buzzreach has concluded a capital and business alliance agreement with Medley and M3, and has raised funds from DG Resona Ventures No. 1 Limited Liability Partnership.
Through this alliance and procurement, the companies intend to leverage their medical, healthcare, and financial assets to improve the case accumulation rate and clinical trial implementation rate, and to strengthen the social implementation of the Japanese DCT ecosystem.

Background and Purpose of Capital and Business Alliance and Fund Procurement

Drug lag and drug loss caused by delays in new drug development and an increase in unapproved drugs have become major issues in building a stable medical system in Japan. In the clinical trial and clinical research area, there are several issues that need to be resolved in order to promote development and research more rapidly, such as "information on new drugs is not reaching the patients and medical institutions that need it" and "DXing of clinical trial operations is not progressing.

In order to solve these issues, the government has launched a series of measures to revitalize new drug development, such as deregulation, establishment of a clinical trial ecosystem*1, and promotion of DCT*2, and has initiated various initiatives to enable medical institutions conducting clinical trials to become involved in more clinical trials and clinical research earlier.
In DCTs, in particular, we are helping to develop the DX environment necessary to make clinical trials a more accessible medical option through e-recruitment, which recruits patients to participate in clinical trials online; e-consent, which uses electronic consent tools; online medical care, which allows patients to receive clinical trial care at home or at their family doctor; medical support through home nursing at the patient's home; and easing the delivery of investigational drugs to patients' homes, pharmacies, and family doctors. The DX environment is being improved to make clinical trials a more accessible medical option through the easing of delivery of investigational drugs to patients' homes, pharmacies, and family doctors.

In this environment, Buzzreach has developed the clinical trial and clinical research support platform "StudyWorks," the clinical trial information disclosure and management function "smt," case collection support for DCT-type subject recruitment using partner sites*3 , and the patient-specific social networking service "Miraiku" to realize centralized management of clinical trial operations on a platform targeting university hospitals, cancer centers, major group hospitals, etc. StudyWorks", a clinical trial information disclosure and management function "smt", case collection support for DCT-type subject recruitment using partner sites, and "Miraiku", a patient-specific SNS service.

Through the capital alliance and fund procurement with each company, we will not only step forward to solve new issues in the field of clinical trials and clinical research, but also to provide new value to medical institutions and patients who use the services of each company.

1 A system led by the Ministry of Health, Labour and Welfare (MHLW) that allows pharmaceutical companies, medical institutions, regulatory authorities, and patients as subjects to cooperate in efficiently conducting clinical trials.
2 Decentralized Clinical Trials. In the past, clinical trial-related tasks such as patient recruitment, in-hospital treatment, and medication administration were all required to be conducted at the medical institution conducting the clinical trial. Methods that allow patients to participate in clinical trials outside of medical institutions, such as at their family doctors or homes
3 Clinical trial cooperating medical institution for DCT

Buzzreach's future role

Buzzreach will focus on the following through this alliance
Standardization and automation of DX for clinical trial operations based on Study Works
Strengthening the ability to accumulate cases at investigational sites by expanding the network of partner sites
The DCT is a social implementation of Japanese-style DCT that combines the assets of various companies.
Establishment of investigational drug delivery and follow-up system including pharmacy and home care area
Specific contributions to the government's "Clinical Trials Ecosystem Initiative

Representative Comment (Takateru Inokawa, CEO, Buzzreach, Inc.)

The capital alliance and fundraising are the result of collaboration between MEDRAY, a leader in medical DX, M3, a leading medical information service company with approximately 90% of Japanese physicians registered, and M3 Group companies, and DG Resona, which has financial and payment infrastructure, partners with different strengths, The alliance will accelerate the social implementation of the Japanese version of DCT by strengthening the ability to accumulate cases at medical institutions conducting clinical trials through the promotion of partner site-based patient recruitment and by utilizing the assets of each partner company.
The Japanese clinical trial DX market is expected to expand rapidly in the future, backed by policy support and the digitization of clinical trial sites. As a "leading platform for social implementation of Japanese-style DCT" in this growing field, we will promote standardization of clinical trial infrastructure across industry, government, and academia through this alliance.
We will continue to collaborate with a wide variety of partners to create a new clinical trial infrastructure that organically links patients, medical institutions, and pharmaceutical companies, based on our philosophy of "providing new options to as many patients as possible through the power of technology.

Contribution to University Hospitals, etc. through this alliance

Many university hospitals, which play a central role in Japan's clinical trial environment, have been forced to operate at a severe loss due to soaring prices and labor costs, cuts in operating subsidies, etc. It is reported that 86% of hospitals will be in the red in FY2023, making stable hospital management difficult based on medical revenue alone. The situation is such that it is difficult to run a hospital stably on medical revenue alone.
As a part of efforts to overcome this situation, we will contribute to the development of university hospitals that conduct many clinical trials, the acceleration of clinical trials, and the implementation of medical innovation by developing a clinical trial infrastructure that will lead to increased efficiency in clinical trial operations and support for improved case accumulation through this alliance.

*Citation:Ministry of Health, Labour and Welfare_Survey on understanding the managerial impact of non-medical services on the main business (P.46-57)

Buzzreach Corporation|Overview

name of companyBuzzreach Inc.
EstablishmentJun 2017
LocationKowa Shirokanedai Building, 19-1, Shirokanedai 3-chome, Minato-ku, Tokyo
representativeRepresentative Director and CEO
Business OverviewPlanning, development and operation of clinical trials and clinical research support platform
Main services: Provision of clinical trial and clinical research support SaaS, DCT support business, development and operation of patient recruitment platform utilizing partner sites, patient SNS business, etc.
uniform resouce locatorhttps://www.buzzreach.co.jp

Medley Corporation|Outline

name of companyMedley Corporation
LocationRoppongi Hills Mori Tower 13F, 6-10-1 Roppongi, Minato-ku, Tokyo
representativeKohei Takiguchi, President and Representative Director
Business OverviewMedical platform business (CLINICS, MALL, DENTIS, MEDIXS, MINET, etc.), Human resources platform business (JobMedley, JobMedley Academy, etc.)
uniform resouce locatorhttps://www.medley.jp

M3 Corporation|Overview

name of companyM3 Corporation
LocationAkasaka Intercity, 1-11-44 Akasaka, Minato-ku, Tokyo
representativeRepresentative Director Itaru Tanimura
Business OverviewProviding medical-related services via the Internet
uniform resouce locatorhttps://corporate.m3.com

DG Resona Ventures No.1 Investment Limited Partnership|Outline

name of companyDG Resona Ventures No.1 Investment Limited Partnership
Location15-1 Udagawa-cho, Shibuya-ku, Tokyo
Business OverviewCVC fund established to jointly promote open innovation and startup investment with the aim of creating business collaboration and synergies between Digital Garage (DG) and the Resona Group
uniform resouce locatorhttps://dg-resona-v.com/

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。